Founder and Managing Director
Gregg applies more than 20 years of experience in the life science and technology industries, ranging from venture-backed start-ups to publicly traded companies. He previously served as CFO of two public and three privately held companies, during which time he managed finance, accounting, corporate communications, human resources, information technology, facilities, legal, intellectual property, business development and manufacturing functions. Gregg’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device, and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg holds a BA from Middlebury College, JD from the University of Pittsburgh School of Law and MBA from Carnegie Mellon University.
Founder and Managing Director
Daniel brings more than 20 years of experience in the life science and renewable energy industries to his work with Danforth clients, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He previously served as COO or CFO of four publicly traded and four privately held companies, in addition to his consulting clients, and was interim CEO of a medical device company. In these roles he had management responsibility for finance, accounting, human resources, investor/public relations, facilities, legal, intellectual property and manufacturing functions. Daniel has raised more than $700 million in equity and debt securities, including a $132 million private placement that was, at the time, the largest PIPE in biotechnology history. His experience spans drafting business plans for pre-Series A companies to managing an orderly wind-down. Daniel started his career as a CPA at KPMG and, later, as a principal in a private equity firm. He is the former Co-Chairman of the Association of Bioscience Financial Officers (ABFO) and of the Finance Committee of the Massachusetts Biotechnology Council. Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.
Steve has more than 30 years of experience in life sciences and healthcare, including founding two start-ups and working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies. He previously served as CFO of two public companies and as CFO, COO, CEO or Director of eight privately held companies, in addition to his consulting clients. He has managed finance, accounting, corporate communications, human resources, information technology, facilities, business development, and manufacturing functions. Steve participated in the successful reorganization of Cambridge Biotech from Chapter 11 bankruptcy protection into Aquila BioPharmaceuticals, led the effort to take RXi public, and has extensive experience in international fundraising and corporate structuring. He was formerly Chairman of Cognoptix and is on the Board of Phytera, Inc. Steve’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. He holds a BS from the University of Massachusetts and MBA from Babson College.
Bill joined Danforth in 2016 to build and lead the Healthcare Technology/Digital Health platform. As a passionate and seasoned CFO with over 25 years of strategic financial and operational management experience, Bill has successfully navigated several companies through rapid growth. His broad experience includes executive leadership with high growth and commercially driven healthcare technology and life science companies such as Humedica (sold to UnitedHealth), NaviNet (sold to Lumeris), SynapDx and ZappRx. Bill has led several successful M&A initiatives, including the highly strategic sale of Humedica to UnitedHealth in 2013. He is recognized for scaling, managing and leading rapidly growing health technology companies and has a successful history of financing via public/private equity transactions, raising more than $300 million. Bill holds a BA from Villanova University and MBA from the University of Massachusetts.
Director of Operations
Christine joined Danforth in 2015 to oversee operations, ranging from recruiting and staffing to administrative management and strategic projects that are core to the firm’s growth. She applies 20 years of finance management experience to the role, providing valuable perspective on how best to serve Danforth clients. Most recently, Christine worked as an independent financial consultant to both corporate and philanthropic organizations. She previously served as CFO of Young Innovations, Inc., a publicly traded medical device company. During her tenure, she identified, transacted and integrated several core acquisitions, led the company’s finance and accounting department, and worked closely with the executive management team and Board of Directors on the strategic options for the organization. Christine also spent six years in investment banking with Robert W. Baird, primarily focused on the healthcare and life science sectors. She began her career as a CPA with Deloitte & Touche in Boston. Christine holds a BA from Bowdoin College and an MBA from the University of Virginia Darden School of Business.